

## Summary Report of Financial Results for the 1<sup>st</sup> Quarter of FY ended December 2015

May 11, 2015

Company Name: Carna Biosciences, Inc.  
 Stock exchange listing: Tokyo Stock Exchange (JASDAQ Growth)  
 Stock Code: 4572  
 URL: <http://www.carnabio.com/english/>  
 Representative: Kohichiro Yoshino, President  
 Contact: Kohichiro Yoshino, Director  
 TEL +81-78-302-7039

(Rounding down to the nearest million yen)

### 1. Consolidated results for the 1<sup>st</sup> quarter of FY2015 (January 1, 2015 - March 31, 2015)

(1) Business Results (Consolidated) (% indicates increases or decreases from the previous first quarter)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
1 <sup>st</sup> quarter of FY2015	334	98.8	98	-	97	-	94	-
1 <sup>st</sup> quarter of FY2014	168	-5.0	-109	-	-111	-	-111	-

	Net income per share	Net income per share (diluted)
	yen	yen
1 <sup>st</sup> quarter of FY2015	11.30	-
1 <sup>st</sup> quarter of FY2014	-13.50	-

Note: Net income per share of 1<sup>st</sup> quarter of FY2014 and 2015(Diluted): No statement - We had net loss per share even though we had diluted shares.

(2) Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio
	million yen	million yen	%
1 <sup>st</sup> quarter of FY2015	1,250	941	74.7
FY2014	1,221	830	67.2

## 2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 <sup>st</sup> quarter period	End of 2 <sup>nd</sup> quarter period	End of 3 <sup>rd</sup> quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2014	-	0.00	-	0.00	0.00
FY2015	-				
FY2015 (forecast)		0.00	-	0.00	0.00

## 3. Forecast of Consolidated Drug Discovery Support segment for FY2015 (January 1, 2015 - December 31, 2015)

(% indicates increases or decreases from the previous year)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share
	million yen	%	million yen	%	million yen	%	million yen	%	Yen
FY2015	917	50.0	406	708.1	-	-	-	-	-

Note: Omitted Forecast of Drug Discovery and Development segment

### \*Disclaimer regarding appropriate use of forecasts and related points of note

The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.